Oberon Investments Nightingale House 65 Curzon Street London, W1J 8PE Stifel Nicolaus Europe Limited 150 Cheapside London EC2V 6ET

Salim Hamir is a Chartered Accountant with extensive leadership experience across public, private, and charitable organizations. He has held pivotal roles at companies such as EKF Diagnostics Holdings, Poolbeg Pharma, Renalytix, Verici Dx, and Trellus Health. As an accomplished CFO, Finance Director, and Company Secretary, Salim brings hands-on expertise in M&A, fundraising, public listings, EIS/VCT, taxation, IFRS reporting, spin-outs, investor relations, restructurings, and corporate governance. His operational involvement has been instrumental in driving the strategic growth and success of companies he has been involved.

Erik Lium, Ph.D. has served as a member of our board of directors since November 2018. Since March 2014, Dr. Lium has served in various roles at Mount Sinai, where he is currently the president of Mount Sinai Innovation Partners, and the executive vice president and chief commercial innovation officer of the Mount Sinai Health System. Dr. Lium represents Mount Sinai on several private company boards and previously served as a member of the investment review committee for the Accelerate NY Seed Fund. Dr. Lium also serves as chairman of the board of managers of Kantaro. Prior to joining Mount Sinai, Dr. Lium served as the assistant vice chancellor of Innovation, Technology & Alliances at the University of California, San Francisco (UCSF), the UCSF principal investigator for the Bay Area National Science Foundation I-Corps node, and assistant vice chancellor of Research. Dr. Lium served as president of LabVelocity Inc. prior to its acquisition in 2004. He pursued postdoctoral research at UCSF in the laboratory of J. Michael Bishop, M.D., earned a Ph.D. from the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University in the laboratory of Dr. Saul J. Silverstein, and holds a B.S. in Biology from Gonzaga University.

Christopher Mills has served as a member of our board of directors since our inception. Mr. Mills founded Harwood Capital Management in 2011, a successor from its former parent company J.O. Hambro Capital Management, which he co-founded in 1993. He is chief executive officer and investment manager of North Atlantic Smaller Companies Investment Trust plc and chairman and chief executive officer of Harwood Capital Management Ltd. Prior to that, Mr. Mills was a Director of Invesco MIM, where he was head of North American Investments and Venture Capital, and of Samuel Montagu International. Mr. Mills currently serves on the board of a number of public companies, including EKF Diagnostics plc, Sureserve Group plc, Augean plc and MJ Gleeson plc. Mr. Mills received a B.A. in Business Studies from Guildhall University.

Fergus Fleming has served as our Chief Technology Officer since our inception. Mr. Fleming has served as managing director of FF Consulting Limited, providing Product Development and Commercialization support to Medical Devices and Diagnostics companies since June 2013. Roles in this period include Head of Business Development for Oncomark Limited from November 2016 to October 2018 and from 2013, he served in various roles at EKF Diagnostics plc. He has over 30 years of experience in the life sciences sector, including leadership positions with Baxter Healthcare, Boston Scientific and Trinity Biotech plc. Mr. Fleming received a degree in Science from University College Galway, Ireland.

FAQs Archive - Page 2 of 3

Joint Broker

Oberon Investments Nightingale House 65 Curzon Street London, W1J 8PE [...]

By Elise Wilfinger|2024-10-28T19:34:20+00:0001.10.23|Advisors|0 Comments

Nominated Advisor

Stifel Nicolaus Europe Limited 150 Cheapside London EC2V 6ET

By Elise Wilfinger|2023-01-10T08:33:07+00:0001.10.23|Advisors|0 Comments

Salim Hamir
FCA

Salim Hamir is a Chartered Accountant with extensive leadership experience [...]

By Elise Wilfinger|2024-11-06T18:54:18+00:0001.10.23|Company Secretary|0 Comments

Erik Lium
PhD

Erik Lium, Ph.D. has served as a member of our board [...]

By Elise Wilfinger|2023-02-27T14:54:48+00:0001.10.23|Non Executive Directors|0 Comments

Christopher Mills

Christopher Mills has served as a member of our board of [...]

By Elise Wilfinger|2023-01-10T08:25:01+00:0001.10.23|Non Executive Directors|0 Comments

Michael J. Donovan
PhD, MD

Michael J. Donovan, Ph.D., M.D. has served as our Chief Medical [...]

By Elise Wilfinger|2023-11-13T17:13:59+00:0001.10.23|Executive Leadership|0 Comments

Joel R. Jung
MBA, Interim CFO

Joel R. Jung joined Renalytix as interim Chief Financial Officer [...]

By Elise Wilfinger|2024-06-23T19:06:58+00:0001.10.23|Executive Leadership|0 Comments

Howard Doran
President

Howard Doran served as our Chief Business Officer from September [...]

By Graham Dyer|2024-06-24T13:03:27+00:0001.10.23|Executive Leadership|0 Comments

Fergus Fleming
CTO

Fergus Fleming has served as our Chief Technology Officer since our [...]

By Elise Wilfinger|2023-11-13T17:12:57+00:0001.10.23|Executive Leadership|0 Comments

James McCullough
MBA, CEO

James McCullough has served as our co-founder and Chief Executive Officer [...]

By Elise Wilfinger|2023-02-27T14:48:37+00:0001.10.23|Executive Leadership|0 Comments